HUMAW Humacyte, Inc. - Warrant
$0,01
Prix · Aoû 18, 2026
Données fondamentales au Aoû 12, 2026
Fourchette 52 semaines
$0–$0
0% of range
Note des analystes
—
Objectif de cours
—
P/E (TTM)
—
ROE
-1140.4%
Marge nette
-2003.6%
HUMAW Aperçu de l'action Prix, capitalisation boursière, P/E, EPS, ROE, dette/capitaux propres, fourchette sur 52 semaines
Prix
$0.01
Capitalisation Boursière
—
P/E (TTM)
—
BPA (TTM)
$-0.26
Revenus (TTM)
$2M
Rendement div.
—
ROE
-1140.4%
Dette/Capitaux propres
—
Fourchette 52 semaines
$0 – $0
HUMAW Graphique du cours de l'action OHLCV quotidien avec indicateurs techniques — panoramique, zoom et personnalisez votre vue
Configure
Performance sur 10 ans Tendances du chiffre d'affaires, du bénéfice net, des marges et du BPA
Revenus et bénéfice net
$2M
2024-12-31
→
2025-12-31
BPA
$-0.26
2020-12-31
→
2025-12-31
Flux de trésorerie libre
$-106M
2021-12-31
→
2025-12-31
Marges
-2003.6%
Valorisation Ratios P/E, P/S, P/B, EV/EBITDA — l'action est-elle chère ou bon marché ?
Métrique
Tendance sur 5 ans
HUMAW
Médiane des pairs
Rentabilité Marges brutes, d'exploitation et nettes ; ROE, ROA, ROIC
Métrique
Tendance sur 5 ans
HUMAW
Médiane des pairs
Operating Margin (Marge d'exploitation)
-5306.0%
—
Net Profit Margin (Marge nette)
-2003.6%
—
ROA
-32.1%
—
ROE
-1140.4%
—
ROIC
-3478.2%
—
Santé financière Dette, liquidité, solvabilité — solidité du bilan
Métrique
Tendance sur 5 ans
HUMAW
Médiane des pairs
Current Ratio (Ratio de liquidité)
3.7
—
Quick Ratio (Ratio de liquidité réduite)
2.8
—
Croissance Croissance du chiffre d'affaires, du BPA et du bénéfice net : Année/Année, TCAC 3 ans, TCAC 5 ans
Métrique
Tendance sur 5 ans
HUMAW
Médiane des pairs
Efficacité du capital Rotation des actifs, rotation des stocks, rotation des créances
Métrique
Tendance sur 5 ans
HUMAW
Médiane des pairs
Fondamentaux complets Tous les indicateurs par an — compte de résultat, bilan, flux de trésorerie
Compte de résultat 16
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Revenue | $2M | $0 | |
| Cost of Revenue | $10M | $0 | |
| R&D Expense | $69M | $89M | |
| SG&A Expense | $31M | $26M | |
| Operating Expenses | $110M | $114M | |
| Operating Income | $-108M | $-114M | |
| Interest Income | $3M | $4M | |
| Other Non-op | $67M | $-34M | |
| Pretax Income | $-41M | · | |
| Income Tax | $0 | $0 | |
| Net Income | $-41M | $-149M | |
| EPS (Basic) | $-0.26 | $-1.26 | |
| EPS (Diluted) | $-0.26 | $-1.26 | |
| Shares (Basic) | 158,160,468 | 118,479,097 | |
| Shares (Diluted) | 158,160,468 | 118,479,097 | |
| EBITDA | $-108M | $-114M |
Bilan 24
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $50M | $45M | |
| Receivables | $441.0K | $0 | |
| Inventory | $14M | $0 | |
| Prepaid Expense | $3M | $3M | |
| Current Assets | $68M | $48M | |
| PP&E (Net) | $19M | $23M | |
| PP&E (Gross) | $60M | $59M | |
| Accum. Depreciation | $41M | $36M | |
| Other Non-current Assets | $672.0K | $1M | |
| Total Assets | $116M | $138M | |
| Accounts Payable | $5M | $4M | |
| Accrued Liabilities | $11M | $11M | |
| Current Liabilities | $18M | $20M | |
| Capital Leases | · | $500.0K | |
| Deferred Tax | $762.0K | $1M | |
| Other Non-current Liabilities | $2M | $983.0K | |
| Total Liabilities | $113M | $191M | |
| Long-term Debt | $35M | $0 | |
| Common Stock | $20.0K | $13.0K | |
| Paid-in Capital | $730M | $633M | |
| Retained Earnings | $-727M | $-686M | |
| Stockholders' Equity | $3M | $-53M | |
| Liabilities + Equity | $116M | $138M | |
| Shares Outstanding | 193,000,611 | 130,027,509 |
Flux de trésorerie 8
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Stock-based Comp | $10M | $6M | |
| Operating Cash Flow | $-105M | $-98M | |
| CapEx | $884.0K | $2M | |
| Investing Cash Flow | $-884.0K | $-2M | |
| Financing Cash Flow | $61M | $114M | |
| Net Change in Cash | $-44M | $14M | |
| Taxes Paid | $0 | $0 | |
| Free Cash Flow | $-106M | $-100M |
Rentabilité 7
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -5306.0% | · | |
| Net Margin | -2003.6% | · | |
| Pretax Margin | -2003.6% | · | |
| EBITDA Margin | -5306.0% | · | |
| ROA | -32.1% | -111.8% | |
| ROE | -1140.4% | 255.5% | |
| ROIC | -3478.2% | · |
Liquidité et Solvabilité 2
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 3.7 | 2.4 | |
| Quick Ratio | 2.8 | 2.3 |
Efficacité 3
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.0 | · | |
| Inventory Turnover | 1.4 | · | |
| Receivables Turnover | 9.2 | · |
Valorisation (TTM) 2
| Métrique | Tendance | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $2M | $0 | |
| Net Income TTM | $-41M | $-149M |
Compte de résultat 16
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $406.0K | $495.0K | $467.0K | $753.0K | $301.0K | $517.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Cost of Revenue | $1M | $2M | $9M | $260.0K | $213.0K | $147.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $18M | $19M | $15M | $17M | $22M | $15M | $21M | $23M | $24M | $21M | $20M | $19M | $21M | $17M | $15M | $17M | |
| SG&A Expense | $8M | $8M | $8M | $8M | $8M | $8M | $7M | $7M | $6M | $5M | $6M | $6M | $6M | $5M | $6M | $6M | |
| Operating Expenses | $27M | $29M | $31M | $25M | $30M | $24M | $28M | $30M | $29M | $27M | $26M | $25M | $27M | $23M | $21M | $24M | |
| Operating Income | $-27M | $-29M | $-31M | $-24M | $-30M | $-23M | $-28M | $-30M | $-29M | $-27M | $-26M | $-25M | $-27M | $-23M | $-21M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $2M | · | $1M | $2M | $2M | $2M | $2M | |
| Interest Income | $388.0K | $330.0K | $503.0K | $590.0K | $832.0K | $662.0K | $852.0K | $911.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $883.0K | |
| Other Non-op | $-10M | $11M | $6M | $7M | $-8M | $62M | $7M | $-9M | $-27M | $-5M | $1M | $-1M | $4M | $-14M | $17M | $-2M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-37M | $-18M | $-25M | $-18M | $-38M | $39M | $-21M | $-39M | $-57M | $-32M | $-25M | $-26M | $-23M | $-37M | $-4M | $-25M | |
| EPS (Basic) | $-0.16 | $-0.09 | $-0.19 | $-0.11 | $-0.24 | $0.28 | $-0.16 | $-0.33 | $-0.48 | $-0.29 | $-0.24 | $-0.25 | $-0.22 | $-0.36 | $-0.04 | $-0.25 | |
| EPS (Diluted) | $-0.16 | $-0.09 | $-0.19 | $-0.11 | $-0.24 | $0.28 | $-0.16 | $-0.33 | $-0.48 | $-0.29 | $-0.24 | $-0.25 | $-0.22 | $-0.36 | $-0.03 | $-0.25 | |
| Shares (Basic) | 234,182,284 | 197,846,786 | -287,086,980 | 158,313,290 | 155,437,281 | 131,496,877 | -228,350,157 | 119,408,565 | 119,174,681 | 108,246,008 | -206,649,037 | 103,444,246 | 103,361,501 | 103,263,528 | -205,990,353 | 103,031,980 | |
| Shares (Diluted) | 234,182,284 | 197,846,786 | -287,349,405 | 158,313,290 | 155,437,281 | 131,759,302 | -228,350,157 | 119,408,565 | 119,174,681 | 108,246,008 | -206,649,037 | 103,444,246 | 103,361,501 | 103,263,528 | -206,893,142 | 103,031,980 | |
| EBITDA | $-27M | $-29M | · | $-24M | $-30M | $-23M | · | $-30M | $-29M | $-27M | · | $-25M | $-27M | $-23M | · | $-23M |
Bilan 25
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $80M | $49M | $50M | $19M | $38M | $63M | $45M | $21M | $94M | $116M | $80M | $100M | $115M | $130M | $150M | $164M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | $0 | $0 | $2M | $2M | $8M | |
| Receivables | $330.0K | $434.0K | $441.0K | $1M | $394.0K | $488.0K | $0 | · | · | · | · | $0 | $0 | $0 | $31.0K | $31.0K | |
| Inventory | $7M | $10M | $14M | $18M | $11M | $8M | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $6M | $5M | $3M | $2M | $2M | $2M | $3M | $2M | $3M | $2M | $3M | $3M | $6M | $2M | $2M | $3M | |
| Current Assets | $93M | $64M | $68M | $41M | $52M | $74M | $48M | $23M | $96M | $118M | $83M | $103M | $121M | $134M | $154M | $175M | |
| PP&E (Net) | $16M | $17M | $19M | $20M | $21M | $22M | $23M | $24M | $25M | $26M | $27M | $28M | $29M | $30M | $30M | $31M | |
| PP&E (Gross) | · | · | $60M | $60M | $60M | $60M | $59M | $59M | $59M | $58M | $58M | $58M | $57M | $57M | $56M | $56M | |
| Accum. Depreciation | · | · | $41M | $40M | $39M | $37M | $36M | $35M | $34M | $33M | $31M | $30M | $29M | $28M | $26M | $25M | |
| Other Non-current Assets | $672.0K | $672.0K | $672.0K | $672.0K | $1M | $1M | $1M | $1M | $815.0K | $828.0K | $632.0K | $855.0K | · | · | $682.0K | · | |
| Total Assets | $138M | $111M | $116M | $92M | $139M | $163M | $138M | $115M | $138M | $161M | $128M | $149M | $168M | $183M | $204M | $226M | |
| Accounts Payable | $4M | $5M | $5M | $10M | $7M | $6M | $4M | $7M | $6M | $3M | $6M | $3M | $2M | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $9M | $11M | $10M | $9M | $10M | $11M | $11M | $9M | $8M | $9M | $10M | $7M | $6M | $7M | $8M | |
| Current Liabilities | $15M | $16M | $18M | $26M | $21M | $20M | $20M | $21M | $18M | $14M | $18M | $15M | $11M | $24M | $20M | $18M | |
| Capital Leases | · | · | · | · | · | · | · | · | · | · | $600.0K | · | · | $620.0K | $600.0K | $645.0K | |
| Deferred Tax | · | · | $762.0K | · | · | · | $1M | · | · | · | $2M | · | · | · | $2M | · | |
| Other Non-current Liabilities | $2M | $2M | $2M | $520.0K | $984.0K | $951.0K | $983.0K | $1M | $1M | $830.0K | $711.0K | $872.0K | $890.0K | · | $712.0K | · | |
| Total Liabilities | $107M | $99M | $113M | $96M | $135M | $127M | $191M | $178M | $167M | $135M | $115M | $112M | $107M | $101M | $87M | $108M | |
| Long-term Debt | $36M | $36M | $35M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Common Stock | $28.0K | $23.0K | $20.0K | $16.0K | $16.0K | $16.0K | $13.0K | $12.0K | $12.0K | $12.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | $10.0K | |
| Paid-in Capital | $813M | $756M | $730M | $697M | $689M | $683M | $633M | $601M | $598M | $595M | $551M | $549M | $547M | $545M | $543M | $541M | |
| Retained Earnings | $-781M | $-744M | $-727M | $-702M | $-685M | $-647M | $-686M | $-665M | $-626M | $-569M | $-537M | $-512M | $-486M | $-464M | $-427M | $-423M | |
| Stockholders' Equity | $31M | $12M | $3M | $-5M | $4M | $36M | $-53M | $-64M | $-28M | $26M | $14M | $37M | $61M | $82M | $117M | $119M | |
| Liabilities + Equity | $138M | $111M | $116M | $92M | $139M | $163M | $138M | $115M | $138M | $161M | $128M | $149M | $168M | $183M | $204M | $226M | |
| Shares Outstanding | 277,798,105 | 222,019,108 | 193,000,611 | 158,835,303 | 156,342,893 | 155,118,816 | 130,027,509 | 119,842,940 | 119,347,688 | 119,084,353 | 103,673,728 | 103,460,836 | 103,408,248 | 103,329,171 | 103,229,013 | 103,098,768 |
Flux de trésorerie 9
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | $1M | |
| Operating Cash Flow | $-22M | $-25M | $-26M | $-24M | $-26M | $-29M | $-27M | $-23M | $-21M | $-27M | $-19M | $-13M | $-23M | $-19M | $-19M | $-17M | |
| CapEx | $104.0K | $175.0K | $39.0K | $49.0K | $568.0K | $228.0K | $63.0K | $934.0K | $184.0K | $391.0K | $150.0K | $493.0K | $485.0K | $1M | $681.0K | $211.0K | |
| Investing Cash Flow | $-104.0K | $-175.0K | $-39.0K | $-49.0K | $-568.0K | $-228.0K | $-63.0K | $-934.0K | $-184.0K | $-391.0K | $-150.0K | $-493.0K | $2M | $-1M | $5M | $-211.0K | |
| Stock Issued | · | · | · | · | · | · | · | · | $0 | $43M | · | · | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $43M | · | · | · | · | · | · | |
| Financing Cash Flow | $54M | $23M | $57M | $-45M | $2M | $47M | $51M | $849.0K | $-467.0K | $63M | $-335.0K | $-764.0K | $6M | $-409.0K | $-212.0K | $-289.0K | |
| Net Change in Cash | $31M | $-2M | $31M | $-69M | $-25M | $18M | $24M | $-23M | $-22M | $35M | $-20M | $-14M | $-15M | $-20M | $-14M | $-17M | |
| Free Cash Flow | · | $-25M | · | · | · | $-29M | · | · | · | $-28M | · | · | · | $-20M | · | · |
Rentabilité 5
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6649.3% | -5845.5% | · | -3239.0% | -9876.1% | -4484.3% | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | -9064.5% | -3559.4% | · | -2325.4% | -12511.0% | 7570.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -6649.3% | -5845.5% | · | -3239.0% | -9876.1% | -4484.3% | · | · | · | · | · | · | · | · | · | · | |
| ROA | -26.6% | -12.9% | · | -17.0% | -27.2% | 24.2% | · | -29.7% | -37.0% | -18.5% | · | -13.8% | -11.0% | -16.5% | · | -9.6% | |
| ROE | -208.4% | -73.9% | · | 51.1% | 310.8% | 125.9% | · | 293.3% | -345.2% | -59.1% | · | -33.4% | -22.3% | -39.8% | · | -26.0% |
Liquidité et Solvabilité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.2 | 3.9 | · | 1.6 | 2.5 | 3.7 | · | 1.1 | 5.4 | 8.4 | · | 6.8 | 10.6 | 5.7 | · | 9.8 | |
| Quick Ratio | 5.4 | 3.0 | · | 0.8 | 1.8 | 3.2 | · | 1.0 | 5.3 | 8.2 | · | 6.6 | 10.1 | 5.6 | · | 9.6 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | -14.6 | · | -16.8 | -15.6 | -13.3 | · | -14.3 |
Efficacité 3
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.0 | 0.0 | 0.0 | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 1.1 | 1.1 | · | 1.4 | 1.5 | 2.1 | · | · | · | · | · | · | · | · | · | · |
Valorisation (TTM) 10
| Métrique | Tendance | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2M | $2M | · | $2M | $818.0K | $517.0K | · | · | · | · | · | · | · | · | · | · | |
| Net Income TTM | $-110M | $-34M | · | $-55M | $-94M | $-89M | · | $-154M | $-137M | $-118M | · | $-111M | $-48M | $-45M | · | $-40M | |
| Market Cap | $31M | $24M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -0.2 | -0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/S | 15.6 | 11.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 1.0 | 2.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 1.0 | 2.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -1.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / FCF | · | -1.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -545.5% | -145.4% | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
États financiers Compte de résultat, bilan, flux de trésorerie — annuel, sur les 5 dernières années
Compte de résultat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Revenu | $2M | $0 | — | — | — |
| Marge d'exploitation % | -5306.0% | — | — | — | — |
| Résultat net | $-41M | $-149M | $-111M | $-12M | $-26M |
| BPA dilué | $-0.26 | $-1.26 | $-1.07 | $-0.12 | $-0.66 |
Bilan
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio de liquidité | 3.7 | 2.4 | 4.5 | 7.9 | 20.8 |
| Ratio de liquidité réduite | 2.8 | 2.3 | 4.4 | 7.8 | 20.4 |
Flux de trésorerie
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flux de trésorerie libre | $-106M | $-100M | $-76M | $-72M | $-81M |
Mes métriques Votre watchlist personnelle — lignes sélectionnées de Fondamentaux Complets
📊
Choisissez les indicateurs qui vous importent — cliquez sur le ➕ à côté de n'importe quelle ligne dans Fondamentaux Complets ci-dessus.
Votre sélection est enregistrée et vous suit sur tous les tickers.
Détenteurs institutionnels (13F) 9 déclarants · $5K total · Au 30 juin 2026
Institutions qui déclarent détenir cette action dans leur Formulaire SEC 13F trimestriel. Uniquement les positions longues ; un même déclarant peut apparaître deux fois pour des jambes d'options distinctes. Les jambes put/call compensatoires importantes reflètent généralement la tenue de marché ou un inventaire couvert, pas une conviction directionnelle.
Activité institutionnelle — Q2 2026 vs trimestre précédent
| Nouvelles positions | Positions clôturées | Augmenté | Diminué | Variation nette des actions |
|---|---|---|---|---|
| 1 (+1 vs T. préc.) | 0 (-1 vs T. préc.) | 1 (-2 vs T. préc.) | 3 (+1 vs T. préc.) | -49K |
Comparé à Q1 2026. Les dépôts de formulaire 13F de la SEC sont dus dans les 45 jours suivant la fin du trimestre, plus une courte période tampon pour les déposants tardifs — les trimestres encore dans cette fenêtre sont ignorés au profit de la paire la plus récente entièrement déclarée.
| Institution | Valeur | Actions | % de 13F suivies | Type |
|---|---|---|---|---|
| LPL Financial LLC | $2 252 | 234 615 | 45,23% | Actions |
| MILLENNIUM MANAGEMENT LLC | $600 | 62 500 | 12,05% | Option d'achat |
| JANE STREET GROUP, LLC | $480 | 50 000 | 9,64% | Actions |
| Sio Capital Management, LLC | $477 | 49 998 | 9,58% | Actions |
| WOLVERINE ASSET MANAGEMENT LLC | $465 | 48 429 | 9,34% | Actions |
| TWO SIGMA SECURITIES, LLC | $403 | 42 019 | 8,09% | Actions |
| TORONTO DOMINION BANK | $204 | 20 418 | 4,10% | Actions |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $97 | 10 059 | 1,95% | Actions |
| Clear Street Group Inc. | $1 | 90 | 0,02% | Actions |
Initiés de la société 11 initiés · 1 dirigeants · 11 administrateurs
| Dirigeant | Rôle | Dernière activité | Actions détenues | Achats 12m | Ventes 12m | Net 12m |
|---|---|---|---|---|---|---|
| Laura E Niklason | President, CEO and Director | 11 juin 2026 A | — | 0 | 0 | $0 |
| Keith Anthony Jones | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| John Philip Bamforth | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Charles Bruce Green | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Diane Seimetz | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Emery N. Brown | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Brady W Dougan | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Max N. Wallace | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Michael T. Constantino | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Susan Richards Windham-Bannister | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
| Kathleen Sebelius | Administrateur | 11 juin 2026 A | — | 0 | 0 | $0 |
Initiés issus des déclarations SEC Form 3/4/5 ; net = uniquement P/S de marché
Activistes et détenteurs de 5%+ 2 participations
Investisseurs ayant déposé un Schedule 13D auprès de la SEC — détention effective supérieure à 5% avec l'intention d'influencer l'émetteur (participations activistes, campagnes pour le conseil d'administration, fusions-acquisitions). Chaque ligne montre le dernier état connu de la position du déposant.
| Déclarant | Déposé | Participation | Statut | Objectif | Dépôt |
|---|---|---|---|---|---|
| Fresenius Medical Care AG, Fresenius Medical Care Holdings, Inc. | 18 août 2026 | 4,90% | Amendement | — | SEC |
| Fresenius Medical Care Holdings, Inc., Fresenius Medical Care AG ×2 dépôts | 13 juillet 2026 | 6,80% | Amendement | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.